respiratori
syncyti
viru
rsv
fusion
f
glycoprotein
major
target
neutral
antibodi
aris
natur
infect
antibodi
specif
bind
prefus
conform
rsv
f
gener
demonstr
greatest
neutral
potenc
prefusionstabil
rsv
f
variant
engin
vaccin
antigen
crystal
structur
variant
reveal
conform
differ
key
antigen
site
locat
apex
trimer
refer
antigen
site
current
unclear
flexibl
region
inher
properti
prefus
rsv
f
relat
inadequ
stabil
site
engin
variant
therefor
set
investig
conform
flexibl
antigen
site
well
abil
human
immun
system
recogn
altern
conform
site
determin
crystal
structur
prefus
rsv
f
bound
neutral
humanderiv
antibodi
antibodi
bound
high
affin
specif
prefus
conform
rsv
f
crystal
structur
complex
reveal
antibodi
recogn
distinct
conform
antigen
site
diverg
conserv
prolin
residu
locat
middl
data
suggest
antigen
site
exist
ensembl
conform
individu
antibodi
recogn
discret
state
collect
result
implic
refold
pneumoviru
paramyxoviru
fusion
protein
inform
develop
prefusionstabil
rsv
f
vaccin
candid
respiratori
syncyti
viru
rsv
pervas
pathogen
caus
sever
lower
respiratori
tract
infect
lead
death
global
year
hundr
million
dollar
healthcar
cost
howev
despit
preval
vaccin
rsv
avail
therapi
limit
highrisk
infant
leav
vast
major
peopl
effect
mean
prevent
treatment
rsv
fusion
f
protein
major
target
neutral
antibodi
includ
extrem
potent
antibodi
plo
pathogen
http
doirecogn
prefusionspecif
epitop
studi
determin
crystal
structur
two
neutral
human
antibodi
bound
prefus
rsv
f
result
reveal
antibodi
recogn
differ
conform
neutralizationsensit
epitop
suggest
region
inher
flexibl
may
import
rsv
f
function
result
guid
futur
vaccinedesign
effort
help
elucid
mechan
rsv
f
trigger
fusion
conform
flexibl
antigen
site
plo
pathogen
http
doi
respiratori
syncyti
viru
rsv
ubiquit
pneumoviru
infect
nearli
children
us
age
two
repeat
infect
occur
throughout
life
rsv
common
caus
acut
lower
respiratori
tract
infect
young
children
elderli
result
estim
death
global
children
age
five
although
death
children
unit
state
attribut
rsv
sever
infect
requir
hospit
frequent
lead
estim
direct
health
care
cost
million
dollar
annual
current
vaccin
rsv
fdaapprov
therapi
passiv
prophylaxi
monoclon
antibodi
palivizumab
synagi
howev
high
cost
modest
efficaci
palivizumab
restrict
usag
highrisk
infant
make
develop
improv
intervent
global
health
prioriti
rsv
envelop
viru
pneumovirida
famili
singlestrand
negativesens
rna
genom
two
subtyp
rsv
b
mani
individu
strain
belong
rsv
two
major
glycoprotein
viral
surfac
import
entri
fusion
f
attach
g
glycoprotein
wherea
rsv
g
primari
sourc
sequenc
variat
defin
subtyp
specif
viru
fusion
glycoprotein
well
conserv
sequenc
ident
rsv
f
class
fusion
glycoprotein
initi
produc
inact
precursor
subsequ
cleav
furinlik
proteas
gener
protom
disulfidelink
subunit
three
protom
associ
form
function
trimer
glycoprotein
requir
membran
fusion
infect
numer
vaccin
trial
rsv
current
underway
mani
contain
rsv
f
glycoprotein
antigen
shown
f
major
target
neutral
antibodi
protein
viral
surfac
strictli
requir
entri
rsv
f
initi
fold
metast
prefus
conform
fusion
peptid
buri
within
central
caviti
trimer
viral
entri
rsv
f
trigger
undergo
dramat
conform
rearrang
prefus
postfus
state
trigger
process
result
releas
fusion
peptid
central
caviti
trimer
insert
targetcel
membran
result
format
unstabl
prehairpin
intermedi
collaps
intermedi
stabl
postfus
conform
bring
viru
hostcel
membran
togeth
facilit
format
fusion
pore
releas
viral
genom
target
cell
howev
mechan
underli
caus
rsv
f
trigger
well
understood
recombin
viru
express
rsv
f
protein
surfac
suffici
infect
immort
cell
line
vitro
suggest
rsv
f
facilit
attach
mediat
fusion
absenc
attach
glycoprotein
potenti
rsv
f
receptor
includ
nucleolin
egfr
heparan
sulfat
proteoglycan
among
other
specif
role
may
play
set
natur
infect
remain
defin
addit
vitro
experi
demonstr
rsv
f
propens
trigger
upon
exposur
elev
temperatur
hypoosmot
condit
rsv
f
even
shown
spontan
trigger
refold
time
due
metast
natur
prefus
conform
rais
possibl
rsv
f
specif
receptor
initi
trigger
fusion
rather
spontan
trigger
presenc
attach
factor
heparan
sulfat
proteoglycan
suffici
entri
major
rsvneutral
activ
human
sera
due
antibodi
specif
prefus
conform
f
recent
character
human
antibodi
respons
rsv
f
reveal
prefusionspecif
antigen
site
includ
site
zero
major
target
neutral
antibodi
antigen
site
locat
membranedist
apex
trimer
includ
loop
connect
loop
loop
upon
trigger
site
undergo
extens
structur
rearrang
loop
refold
form
continu
observ
postfus
f
conform
comparison
neutral
potenc
two
site
antibodi
palivizumab
site
iidirect
conformationindepend
antibodi
demonstr
prefusionspecif
antibodi
time
potent
potent
prefusionspecif
human
antibodi
bind
apex
trimer
also
isol
recent
year
one
advanc
stage
clinic
develop
first
structur
character
antibodi
specif
target
prefus
rsv
f
use
solv
structur
prefus
rsv
f
conform
facilit
engin
prefusionstabil
variant
prevent
conform
rearrang
postfus
rsv
f
recent
structur
bound
rsv
f
determin
reveal
nearli
ident
conform
prefus
rsv
f
observ
structur
howev
crystal
structur
differ
prefusionstabil
variant
rsv
f
reveal
altern
conform
antigen
site
weak
electron
densiti
region
suggest
site
flexibl
current
unclear
flexibl
region
inher
properti
prefus
rsv
f
may
import
trigger
membran
fusion
relat
inadequ
stabil
site
engin
variant
therefor
sought
investig
conform
plastic
site
determin
compar
crystal
structur
prefus
rsv
f
complex
result
demonstr
prefus
rsv
f
adopt
least
three
altern
conform
site
potent
neutral
human
antibodi
recogn
altern
conform
use
distinct
bind
mode
suggest
site
sampl
ensembl
conform
vivo
least
recogn
neutral
human
antibodi
result
influenc
futur
vaccin
design
may
implic
mechan
rsv
f
trigger
previou
studi
demonstr
potent
neutral
rsv
preferenti
bind
prefus
rsv
f
conform
similar
previous
character
site
antibodi
howev
differ
antibodi
kinet
subtyp
specif
fulli
explor
therefor
use
surfac
plasmon
reson
spr
determin
bind
affin
kinet
interact
three
site
antibodi
prefus
rsv
f
deriv
subtyp
strain
fig
studi
work
germlinerevert
version
kinet
paramet
antibodi
bind
prefus
rsv
f
surfac
plasmon
reson
spr
sensorgram
fab
bind
prefus
rsv
f
subtyp
strain
b
subtyp
b
strain
raw
data
plot
black
line
fit
curv
use
calcul
bind
kinet
plot
thicker
red
line
bind
curv
second
associ
phase
follow
second
dissoci
phase
equilibrium
dissoci
constant
k
display
immedi
spr
curv
fab
c
tabl
associ
rate
constant
k
dissoci
rate
constant
k
determin
bind
kinet
fab
valu
x
use
lower
limit
dissoci
rate
constant
k
accur
measur
biacor
somat
mutat
framework
region
revert
germlin
residu
minim
immunogen
fig
note
show
similar
neutral
potenc
bind
kinet
prefus
rsv
f
compar
parent
antibodi
fig
despit
similar
neutral
potenc
display
distinct
affin
bind
kinet
compar
well
compar
individu
across
two
rsv
subtyp
antigenbind
fragment
fab
higher
affin
subtyp
equilibrium
dissoci
constant
k
nm
wherea
affin
subtyp
b
nm
similarli
fab
bind
tightli
prefus
rsv
f
slight
prefer
subtyp
consist
previous
publish
data
k
nm
nm
subtyp
b
respect
contrast
fab
substanti
subtyp
specif
stronger
affin
subtyp
b
compar
subtyp
k
nm
nm
respect
preferenti
bind
subtyp
b
primarili
due
offrat
fast
subtyp
interact
slow
subtyp
b
interact
investig
conform
site
defin
epitop
prefus
rsv
f
recogn
determin
crystal
structur
fab
alon
complex
prefusionstabil
rsv
f
variant
crystal
fab
alon
diffract
xray
crystal
prefus
rsv
complex
diffract
xray
tabl
variabl
domain
fv
superimpos
well
bound
unbound
crystal
structur
high
structur
similar
across
framework
complementaritydetermin
region
cdr
result
rmsd
atom
crystal
structur
complex
show
three
fab
bind
prefus
rsv
f
membranedist
apex
trimer
vertic
angl
approach
fig
agreement
previous
publish
neg
stain
em
imag
buri
surfac
area
protom
prefus
rsv
f
mediat
primarili
interact
heavi
chain
subunit
heavi
chain
buri
surfac
prefus
rsv
f
involv
hydrogen
bond
rsv
f
form
cdr
seven
residu
within
loop
prefus
rsv
f
light
chain
respons
remain
buri
surfac
area
prefus
rsv
f
form
three
addit
hydrogen
bond
loop
via
cdr
high
affin
specif
prefus
rsv
f
fig
fig
due
format
threestrand
antiparallel
cdr
loop
fig
bound
kink
near
residu
shift
away
stretch
loop
allow
adopt
conform
pair
form
cdr
upon
rsv
f
trigger
rearrang
postfus
conform
loop
refold
continu
would
disrupt
interact
prevent
bind
sequenc
comparison
two
rsv
f
subtyp
demonstr
residu
compris
epitop
wellconserv
howev
one
subtyp
rsv
f
residu
contact
gln
subtyp
b
fig
side
chain
subtyp
prefus
rsv
f
coordin
three
residu
heavi
chain
includ
format
salt
bridg
cdr
effect
extend
promin
interact
substitut
gln
found
subtyp
b
would
elimin
salt
bridg
may
explain
subtyp
prefer
inde
incorpor
investig
conform
variabl
site
identifi
epitop
prefus
rsv
f
recogn
determin
crystal
structur
prefus
rsv
f
complex
fab
resolut
tabl
crystal
structur
show
three
fab
bind
membranedist
apex
prefus
rsv
f
trimer
fig
bind
slightli
lower
trimer
bridg
antigen
site
recent
defin
site
v
interact
prefus
rsv
f
divers
cdr
cdr
well
three
cdr
light
chain
make
contact
f
protein
fig
addit
contact
prefus
rsv
f
span
multipl
region
includ
loop
well
buri
total
surfac
area
heavi
chain
buri
surfac
prefus
rsv
f
cdr
interact
loop
form
hydrogen
bond
mainchain
atom
respect
wherea
cdr
contact
form
salt
bridg
light
chain
contribut
interfac
contact
includ
hydrogen
bond
mainchain
atom
similar
prefus
specif
explain
dramat
rearrang
form
singl
elong
upon
convers
postfus
conform
dismantl
epitop
bind
mode
angl
approach
differ
three
site
antibodi
fig
adopt
vertic
angl
approach
bind
apex
trimer
agreement
previou
neg
stain
em
imag
contrast
diagon
angl
approach
bind
slightli
lower
prefus
rsv
f
bridg
antigen
site
v
similar
recent
character
antibodi
despit
differ
epitop
three
antibodi
overlap
significantli
larg
steric
clash
would
prevent
two
antibodi
bind
simultan
fig
specif
three
antibodi
make
multipl
compet
contact
loop
addit
extent
antibodi
interact
subunit
vari
greatli
three
antibodi
interfac
account
buri
surfac
area
prefus
rsv
f
includ
two
hydrogen
bond
interfac
contribut
buri
surfac
area
includ
five
hydrogen
bond
four
residu
within
contrast
interfac
account
buri
surfac
area
prefus
rsv
f
form
hydrogen
bond
salt
bridg
thu
wherea
make
sever
contact
loop
interact
almost
exclus
subunit
top
view
ribbonandstick
represent
color
highlight
hydrogen
bond
interact
cdr
light
chain
hidden
lowerleft
panel
panel
right
clariti
stick
model
oxygen
atom
color
red
nitrogen
blue
sulfur
yellow
c
amino
acid
sequenc
rsv
f
site
shown
strain
strain
diamond
symbol
residu
indic
contact
prefus
rsv
f
strain
base
upon
pdbepisa
analysi
crystal
structur
http
fig
structur
complex
show
open
conform
site
kink
away
result
stretch
loop
larger
angl
helic
structur
close
match
unbound
prefusionstabil
rsv
f
variant
pdb
id
prdm
pdb
id
specif
kink
greater
angl
contrast
prefus
rsv
structur
close
conform
site
kink
smaller
angl
structur
bound
reveal
intermedi
site
conform
slightli
kink
away
degre
seen
complex
three
antibodi
isol
human
experienc
natur
rsv
infect
structur
indic
site
natur
flexibl
adopt
least
three
state
recogn
human
immun
system
also
possibl
perhap
like
site
exist
ensembl
mani
conform
three
trap
antibodi
two
human
antibodi
bind
antigen
site
specif
prefus
conform
rsv
f
although
antibodi
potent
neutral
rsv
similar
bind
kinet
subtyp
specif
distinct
differ
preferenti
bind
subtyp
wherea
preferenti
bind
subtyp
b
result
fast
dissoci
rate
constant
subtyp
f
protein
addit
previou
public
use
spr
flow
cytometrybas
competit
assay
suggest
compet
rather
occupi
separ
prefusionspecif
epitop
howev
compar
crystal
structur
prefus
rsv
f
bound
demonstr
three
antibodi
epitop
overlap
substanti
would
prevent
two
bind
simultan
due
larg
steric
clash
emphas
import
structur
character
antibodi
epitop
addit
competit
data
vari
antibodi
kinet
mislead
epitop
classif
use
competit
assay
structur
studi
present
reveal
altern
conform
rsv
f
site
prefus
state
suggest
natur
flexibl
region
recogn
numer
way
humor
immun
system
conform
flexibl
support
crystal
structur
multipl
prefusionstabil
variant
identifi
array
site
conform
high
atom
b
factor
distinct
lack
site
electron
densiti
pdb
id
pink
b
closeup
side
view
interact
one
fab
one
rsv
f
protom
ribbonandstick
represent
rotat
color
stick
model
oxygen
atom
color
red
nitrogen
blue
sulfur
yellow
c
ribbonandstick
model
cdr
loop
contact
one
protom
rsv
f
shown
molecular
surfac
color
b
rotat
indic
amino
acid
sequenc
residu
near
rsv
f
site
site
v
shown
strain
strain
diamond
symbol
residu
indic
contact
prefus
rsv
f
strain
base
upon
pdbepisa
analysi
crystal
structur
http
represent
singl
fab
bound
apex
rsv
f
trimer
view
look
along
toward
viral
membran
three
rsv
f
protom
color
light
green
tan
pink
color
purpl
color
red
color
blue
b
surfac
represent
apex
rsv
f
trimer
highlight
epitop
antibodi
singl
f
protom
epitop
antibodi
shown
green
protom
epitop
color
purpl
red
blue
c
amino
conform
flexibl
transient
exposur
differ
epitop
note
class
fusion
protein
env
merscov
spike
specif
ident
residu
loop
env
shown
adopt
differ
conform
bound
two
differ
neutral
antibodi
demonstr
structur
plastic
import
neutral
epitop
comparison
two
prefusionstabil
rsv
f
variant
ds
pdb
id
pdb
id
highlight
flexibl
site
suggest
conform
rearrang
site
requir
prior
releas
fusion
peptid
central
caviti
trimer
refold
prefus
postfus
state
fusion
peptid
anchor
disulfid
bond
ds
structur
pdb
id
site
acid
sequenc
residu
near
rsv
f
site
shown
strain
strain
diamond
symbol
residu
indic
contact
prefus
rsv
f
strain
base
upon
pdbepisa
analysi
crystal
structur
http
conform
heterogen
indic
lack
electron
densiti
howev
site
cavityfil
mutat
introduc
pdb
id
pdb
id
variant
stabil
prefus
rsv
f
structur
show
clear
electron
densiti
extend
fusion
peptid
site
taken
togeth
suggest
movement
fusion
peptid
condit
upon
prior
rearrang
site
discrep
crystal
structur
wildtyp
prefus
rsv
f
bound
prefusionstabil
variant
kinkedopen
conform
model
attribut
cavityfil
mutat
unabl
fulli
stabil
howev
structur
report
complex
human
antibodi
match
unbound
structur
demonstr
conform
natur
sampl
altern
conform
prefus
rsv
f
recent
vaccin
strategi
target
virus
class
fusion
protein
focus
stabil
prefus
conform
fusion
protein
use
immunogen
common
approach
achiev
prefus
stabil
introduct
one
prolin
residu
within
loop
helixloophelix
motif
refold
continu
alpha
helix
postfus
conform
strategi
use
success
stabil
sever
class
viral
fusion
glycoprotein
includ
rsv
f
mpv
f
influenza
ha
hiv
env
coronaviru
spike
prolinebas
stabil
util
restrict
phipsi
angl
prolin
residu
disrupt
alphahelix
hydrogen
bond
network
inhibit
hing
motion
requir
helixloophelix
motif
subsequ
coiltohelix
structur
transit
requir
refold
postfus
conform
howev
wildtyp
prefus
rsv
f
conserv
prolin
residu
within
middl
ntermin
loop
may
act
hing
refold
crystal
structur
prefus
rsv
f
demonstr
varieti
altern
conform
adopt
antigen
site
diverg
near
conserv
indic
may
disfavor
rigid
alphahel
structur
turn
facilit
conform
flexibl
site
tendenc
prefus
rsv
f
trigger
note
absolut
conserv
human
bovin
rsv
strain
prolin
ident
posit
also
commonli
found
f
protein
virus
within
pneumovirida
paramyxovirida
famili
except
human
metapneumovirus
fig
function
import
wellconserv
prolin
residu
need
evalu
futur
studi
investig
trigger
mechan
refold
pneumoviru
paramyxoviru
f
protein
recent
character
antibodi
repertoir
rsv
f
highlight
import
prefusionspecif
epitop
select
immunogen
rsv
f
vaccin
design
particularli
recent
failur
sever
postfus
rsv
f
vaccin
trial
find
demonstr
potent
neutral
human
antibodi
target
antigen
site
recogn
varieti
altern
conform
vari
degre
subtyp
specif
potent
antibodi
bind
variou
altern
conform
site
propos
ideal
prefus
rsv
f
immunogen
would
maintain
natur
conform
flexibl
site
well
present
neutral
epitop
common
rsv
subtyp
plasmid
encod
prefusionstabil
rsv
f
subtyp
substitut
postfus
rsv
f
base
subtyp
strain
subtyp
b
strain
ctermin
tag
streptag
ii
cotransfect
furin
freestyl
cell
invitrogen
ratio
ensur
full
cleavag
prefus
rsv
f
protein
purifi
media
six
day
use
ninta
superflow
resin
qiagen
streptactin
resin
iba
tag
remov
digest
thrombin
proteas
follow
gel
filtrat
use
superdex
column
ge
healthcar
bioscienc
prefus
rsv
f
protein
use
spr
produc
manner
except
tag
remov
prior
gel
filtrat
crystal
strain
express
presenc
kifunensin
digest
ww
endo
h
overnight
mix
molar
excess
purifi
fab
f
f
complex
respect
result
complex
purifi
size
exclus
chromatographi
sec
use
superos
xk
column
ge
healthcar
bioscienc
buffer
consist
mm
tri
ph
mm
nacl
nan
germlin
sequenc
framework
region
determin
refer
imgt
databas
fulli
germlin
vh
vl
framework
region
defin
imgt
produc
gene
synthesi
genscript
confirm
sequenc
synthes
vh
vl
sequenc
clone
human
express
vector
kindli
provid
michel
nussenzweig
rockefel
univers
new
york
ny
usa
essenti
describ
plasmid
encod
antibodi
heavi
light
chain
cotransfect
cell
freestyl
cell
invitrogen
igg
fab
purifi
use
protein
agaros
fisher
captureselect
affin
matrix
life
technolog
respect
igg
antibodi
elut
protein
column
use
glycin
ph
buffer
solut
contain
vv
tri
ph
fab
elut
captureselect
column
use
mm
acet
acid
ph
buffer
solut
contain
v
v
tri
ph
produc
fab
express
purifi
igg
hrv
proteas
site
hing
heavi
chain
fab
produc
digest
igg
hrv
hour
room
temperatur
follow
pass
solut
protein
resin
remov
fc
subsequ
purifi
sec
use
superdex
column
ge
product
fab
done
incub
igg
papain
bead
pierc
igg
fab
buffer
exchang
use
desalt
column
follow
final
purif
sec
use
superdex
column
ge
prior
long
term
storag
postfus
rsv
f
subtyp
strain
subtyp
b
strain
well
subtyp
mutant
substitut
ctermin
tag
immobil
ninta
sensor
chip
total
respons
unit
use
biacor
ge
bufferonli
sampl
inject
postfus
rsv
f
refer
flow
cell
refer
subtract
follow
serial
dilut
fab
nm
pm
hbsp
duplic
nm
concentr
subtyp
mutant
substitut
fab
evalu
assay
evalu
fab
bind
strain
highest
fab
concentr
use
um
hbsp
buffer
follow
serial
dilut
lowest
concentr
pm
assay
evalu
bind
postfus
rsv
f
subtyp
b
concentr
nm
fab
hbsp
buffer
use
data
doublerefer
subtract
fit
bind
model
use
biacor
analysi
softwar
final
bind
curv
display
use
graphpad
prism
version
window
microneutr
assay
base
infect
cell
rsv
strain
human
monoclon
antibodi
variant
incub
tcid
virus
hour
room
temperatur
addit
target
cell
incub
day
depend
strain
viral
infect
measur
indirect
immunofluoresc
use
autom
pathway
analyz
bd
previous
describ
ic
valu
calcul
interpol
neutral
curv
fit
nonlinear
regress
variabl
slope
diffract
data
process
use
softwar
suit
data
index
integr
imosflm
scale
merg
aimless
molecular
replac
solut
fab
dataset
found
phaser
use
chimer
protein
model
consist
heavi
light
chain
pdb
id
pdb
id
respect
separ
constant
variabl
domain
search
model
structur
built
manual
coot
refin
use
phenix
structur
built
refin
r
work
r
free
tabl
molecular
replac
solut
complex
fab
obtain
use
phaser
prefusionstabil
rsv
f
variant
pdb
id
fab
structur
search
model
asymmetr
unit
contain
prefus
trimer
bound
three
fab
rigidbodi
refin
perform
phenix
follow
refin
group
bfactor
x
z
coordin
phenix
nc
torsion
restraint
referencemodel
restraint
refer
model
prefusionstabil
rsv
f
variant
pdb
id
structur
built
refin
r
work
r
free
tabl
molecular
replac
solut
complex
fab
obtain
use
phaser
prefusionstabil
rsv
f
variant
prdm
pdb
id
chimer
protein
fab
model
consist
heavi
light
chain
pdb
id
pdb
id
respect
separ
constant
variabl
domain
without
fc
domain
heavi
chain
structur
built
manual
coot
refin
use
phenix
rigidbodi
refin
initi
perform
phenix
follow
refin
individu
bfactor
x
z
coordin
phenix
referencemodel
restraint
refer
model
prefus
f
variant
prdm
pdb
id
structur
built
refin
r
work
r
free
tabl
structur
featur
analyz
use
interfac
featur
pdbepisa
analysi
defin
antibodi
epitop
paratop
specif
residu
contact
involv
interfac
well
buri
surfac
area
model
structur
complex
display
use
pymol
facilit
structur
comparison
differ
complex
amino
acid
sequenc
human
respiratori
syncyti
viru
subtyp
strain
fusion
protein
use
origin
sequenc
comparison
known
pneumoviru
paramyxoviru
fusion
protein
ncbi
basic
local
align
search
tool
blast
use
identifi
homolog
region
hrsv
fusion
protein
sequenc
strain
pneumoviru
paramyxoviru
fusion
protein
specif
identifi
sequenc
indic
partial
homolog
residu
hrsv
fusion
protein
sequenc
deriv
strain
residu
correspond
loop
within
prefus
rsv
f
structur
known
structur
prefus
pneumoviru
paramyxoviru
fusion
protein
homolog
sequenc
also
correspond
equival
loop
even
residu
number
differ
prevent
overrepresent
viral
speci
multipl
subtyp
sequenc
includ
singl
amino
acid
sequenc
speci
multipl
subtyp
ident
throughout
residu
rang
correspond
hrsv
f
howev
two
subtyp
within
singl
viral
speci
differ
residu
rang
correspond
hrsv
f
includ
perform
sequenc
analysi
gener
sequenc
weblogo
exampl
four
sequenc
strain
human
metapneumoviru
f
mostli
ident
henc
two
repres
sequenc
includ
final
weblogo
strain
howev
multipl
distinct
sequenc
differ
type
parainfluenza
viru
piv
therefor
distinct
sequenc
includ
separ
gener
weblogo
see
tabl
full
list
sequenc
use
weblogo
weblogo
gener
use
publicli
avail
softwar
weblogoberkleyedu
coordin
structur
factor
complex
unbound
fab
complex
deposit
protein
data
bank
pdb
access
code
respect
mannwhitney
u
test
b
spr
sensorgram
demonstr
parent
similar
bind
affin
kinet
raw
data
plot
black
line
fit
curv
shown
thicker
red
line
bind
curv
second
associ
phase
follow
second
dissoci
phase
equilibrium
dissoci
constant
k
shown
directli
sensorgram
curv
associ
k
dissoci
k
rate
constant
shown
sensorgram
tif
fig
bind
postfus
rsv
f
spr
sensorgram
demonstr
bind
postfus
rsv
f
deriv
subtyp
b
subtyp
b
raw
data
plot
black
line
motavizumab
mota
fab
conformationindepend
antibodi
includ
posit
control
fit
curv
sensorgram
shown
thicker
red
line
bind
curv
second
associ
phase
follow
second
dissoci
phase
tif
fig
bind
decreas
affin
subtyp
prefus
rsv
f
substitut
spr
sensorgram
fab
bind
subtyp
prefus
rsv
f
substitut
raw
data
plot
black
line
fit
curv
use
calcul
bind
kinet
plot
thicker
red
line
bind
curv
second
associ
phase
follow
second
dissoci
phase
equilibrium
dissoci
constant
k
display
immedi
spr
curv
associ
rate
constant
k
dissoci
rate
constant
k
shown
sensorgram
